OVID Company Profile and Key Details

Ovid Therapeutics Inc. (NASDAQ:OVID) closed at $1.60 USD, gaining $0.15 (10.34%) from the previous close of $1.45. The stock is currently mid-range between its 52-week high and low $0.24 and $2.01. With a market capitalization of about $113.94 million, Ovid Therapeutics Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.26). Key stats such as the average daily volume over the past year has been around 1.65 million shares, in line with its 52-week average. Headquartered in New York City, NY, Ovid Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Margaret Alexander, the company employs approximately 23 people and listed since May 05, 2017. Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.

Short-term trend indicators are mixed aligned (SMA20 -0.44%, SMA50 -1.84%, SMA200 52.92%). The stock’s 14-day RSI is 49.97 (neutral), while the ATR of 0.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -20.4% below its high and over 559.79% above its low. Average 10-day trading volume of 2.06 million shares is slightly above the 3-month average of 1.62 million, indicating heightened recent market interest.

Ovid Therapeutics Inc. trades at a P/E ratio of -3.06, slightly below the S&P 500 average, with a price-to-sales ratio of 16.86 and a price-to-book ratio of 2.49 suggesting the stock is closer to book value. The P/FCF stands at -2.94, also above market averages.

Ovid Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.02. This means the shares are trading below this model’s fair value.

Ovid Therapeutics Inc. generated EPS of -$0.51 over the past year. Five-year average earnings growth is 24.72%. Wall Street analysts project EPS growth of -13.2% annually over the next five years. The latest quarter delivered EPS of -$0.17. The next quarter is forecast at -$0.12. Next year's EPS is expected at $14.01. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $2.00. The high target offers 212.5% upside. The low target suggests 25.0% downside. The mean target is $3.29. This offers 105.62% upside. Ovid Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 89.98%. The prior quarter beat by -62.5%. Over the last six quarters, Apple has recorded several small beats. These include -154.55% in August 13, 2024.

Ovid Therapeutics Inc. has 71.11 million shares outstanding. The public float is 59.52 million shares, elevated short interest at 2.70% of float. This equals 1.61 million shares. The short ratio is 0.69 days. Institutional investors hold 41.45% of the float. Insiders own 16.31%. TAKEDA PHARMACEUTICAL CO LTD holds 5.75 million shares, Rakhit Amit has 726.82 thousand shares and ALEXANDER MARGARET A. has 73.41 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.